Aroa Biosurgery (ASX:ARX) has published new clinical evidence demonstrating both the effectiveness and economic value of its Myriad products in complex trauma and acute care surgery, reinforcing the growing role of the company’s bioscaffold technology in high-acuity surgical settings.
The findings, released as part of the ongoing Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR) study, have been published in the Journal of Trauma and Injury. MASTRR is the largest ongoing prospective, multicentre observational study evaluating the use of a bioscaffold in complex soft tissue reconstruction, with more than 450 patients enrolled to date.
The latest publication reports outcomes from 49 patients with a total of 61 traumatic and acute care defects treated across four Level I trauma centres in the United States. These centres manage some of the most severe and complex trauma cases, where wounds are often extensive and contaminated, making reconstruction particularly challenging.
According to the study, wounds treated with Myriad Matrix and Myriad Morcells achieved full vascularised tissue coverage in a median of 22.5 days. In most cases, this outcome was achieved with a single application of the product, and no device-related complications were reported.
In addition to clinical outcomes, the study assessed Myriad's economic performance relative to other bioscaffolds commonly used in trauma and acute care surgery, drawing on previously published data. The comparison showed that Myriad is less expensive per centimetre of coverage and delivers key clinical outcomes that are equivalent to, or better than, alternative bioscaffold options.
Participating study author and trauma surgeon Dr Michael Cormican said the prospective data validated what surgeons were already observing in practice, noting that Myriad provides a cost-effective solution for improving coverage and healing of complex trauma defects without adding risk to patients.
Aroa Chief Executive Officer Brian Ward said the publication represents the third study released from the ongoing MASTRR program and further strengthens the evidence base supporting Myriad’s use in trauma surgery. He highlighted Myriad's potential to reduce the total cost of care for hospitals, particularly given the scale of the trauma market in the United States, where more than 140,000 trauma procedures are performed annually.